Dislipidemia, Studio Milos “Acido bempedoico reduces cardiovascular risk”
MONACO DI BAVIERA (ITALPRESS) – Daiichi Sankyo (TSE:4568) today announced new results of the MILOS study, which demonstrate the impact of bempedoic acid in the management of dyslipidemia in real clinical practice, both in monotherapy and in fixed dose association […]
Dislipidemia, Studio Milos “Acido bempedoico reduces cardiovascular risk” Read More »










